A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects
BAL2420-CP-101
Phase 1 other active
Quick answer
A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects for Severe infections caused by Gram-negative bacteria is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Severe infections caused by Gram-negative bacteria
- Phase
- Phase 1
- Modality
- other
- Status
- active